BioLineRx Ltd. (BLRX) reported recently the completion of patient recruitment in the triple mix arm of its ongoing Phase 2a COMBAT/KEYNOTE -202 study.
” We more than happy to see the triple mix arm of our Phase 2a pancreatic research study advance according to plan,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “This follows extremely appealing preliminary results that existed last month at the ESMO IO conference, demonstrating robust and long lasting responses to the triple mix treatment. As prior to stated, we remain on track to reveal progression-free and general survival information from the triple mix arm in mid-2020.”
An overall of 40 patients identified with unresectable stage IV metastatic pancreatic adenocarcinoma (PDAC), who have advanced following first-line gemcitabine-based therapy, were enrolled as prepared in the triple mix arm focusing on second-line pancreatic cancer patients. Clients receive Motixafortide ( BL-8040) monotherapy priming treatment for 5 days, followed by combination cycles of chemotherapy (Onivyde ®/ 5-fluorouracil/leucovorin), KEYTRUDA ® and Motixafortide until progression. The primary endpoint of the study is the objective action rate (ORR). Secondary endpoints include general survival, development free survival, and illness control rate.
On the other end, the stock has actually been kept in mind 50.97% away from the low rate over the last 52-weeks. The stock altered -0.85% to recent value of $2.34.
The cost continued of -3.65% from the mean of 20 days, -3.88% from mean of 50 days SMA and carried out -34.62% from mean of 200 days cost. Companys performance for the week was -2.50%, 0.00% for month and YTD efficiency remained 4.00%.